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OBJECTIVE: To investigate in a large global sample of patients with retinoblastoma whether sex predilection exists for this
childhood eye cancer.
METHODS: A cross-sectional analysis including 4351 treatment-naive retinoblastoma patients from 153 countries who presented to
278 treatment centers across the world in 2017. The sex ratio (male/female) in the sample was compared to the sex ratio at birth by
means of a two-sided proportions test at global level, country economic grouping, continent, and for selected countries.
RESULTS: For the entire sample, the mean retinoblastoma sex ratio, 1.20, was higher than the weighted global sex ratio at birth,
1.07 (p < 0.001). Analysis at economic grouping, continent, and country-level demonstrated differences in the sex ratio in the
sample compared to the ratio at birth in lower-middle-income countries (n= 1940), 1.23 vs. 1.07 (p= 0.019); Asia (n= 2276),
1.28 vs. 1.06 (p < 0.001); and India (n= 558), 1.52 vs. 1.11 (p= 0.008). Sensitivity analysis, excluding data from India, showed that
differences remained significant for the remaining sample (χ2= 6.925, corrected p= 0.025) and for Asia (χ2= 5.084, corrected p=
0.036). Excluding data from Asia, differences for the remaining sample were nonsignificant (χ2= 2.205, p= 0.14).
CONCLUSIONS: No proof of sex predilection in retinoblastoma was found in the present study, which is estimated to include over
half of new retinoblastoma patients worldwide in 2017. A high male to female ratio in Asian countries, India in specific, which may
have had an impact on global-level analysis, is likely due to gender discrimination in access to care in these countries, rather than a
biological difference between sexes.
Eye; https://doi.org/10.1038/s41433-021-01675-y
INTRODUCTION
Sex has long been recognized as an important factor influencing
cancer risk, incidence, response to treatment and prognosis,
including in children [1, 2]. In retinoblastoma, the most common
intraocular malignancy in children [3], sex-related differences, and
specifically the sex ratio, have not been thoroughly investigated.
This may be attributed to the fact that retinoblastoma is a rare
disease, hence reported study cohorts are relatively too small to
demonstrate any real difference between the sexes. Additionally,
the mutated gene in almost all retinoblastoma cases, RB1, is
assigned to chromosome 13 [4], with only few reports describing a
link to sex chromosomes [5–7].
In most clinical studies on retinoblastoma in which the sex ratio
was recorded, no valid statistical analysis was undertaken to
determine whether a significant difference between sexes existed.
Furthermore, despite the fact that retinoblastoma is a childhood
cancer, most studies did not take into account the sex ratio at birth,
which across the world is >1 in favor of males [8]. In the few studies
that did, results were mixed, showing male [9–11], female [12], or no
preponderance at all [13, 14]. Only a single study based on
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retinoblastoma registries [15], and which showed no difference in
the male-to-female ratio, included data from several countries (19
European countries), whereas all other studies were from a single
country.
In a previous report from our group [16], we presented the
stage of retinoblastoma at time of diagnosis in a large sample of
retinoblastoma patients from over 150 countries. In the present
study, we aimed to investigate the retinoblastoma sex ratio in the
same sample of patients. Our null hypothesis was that there is no
sex difference between cases of retinoblastoma in the population
at risk for retinoblastoma (i.e., children up to 5 years of age).
METHODS
Inclusion and exclusion criteria, patient enrollment and data collection have
previously been described in detail [16]. Briefly, we conducted a 1-year
observational cross-sectional analysis, including consecutive treatment-naive
retinoblastoma patients who presented from January 1, 2017 to December
31, 2017 to participating retinoblastoma treatment centers (n= 278). Data
collected included patient country of residence, sex, age at presentation to
the retinoblastoma center, laterality at the time of diagnosis, family history of
retinoblastoma, and staging according to the 8th edition of the American
Joint Committee on Cancer clinical Tumor, Node, Metastasis, Heredity
(cTNMH) scheme [17]. The study was approved by the London School of
Hygiene & Tropical Medicine institutional review board (reference no. 14574)
in accordance with the tenets of the Declaration of Helsinki. Participating
centers, according to local institutional and national guidelines, applied to
and received ethics clearance in their countries.
Statistical analysis
All analyses were performed using R software [18]. The sex ratio (male/
female) at birth for each country was obtained from the World Population
Prospects [19], and the data were compared to the sex ratio in the present
sample. Comparisons were performed at global, country economic
grouping, continent and individual country level (including countries with
samples >150 patients); and a two-sided proportions test (χ2 test of
homogeneity, χ2 goodness of fit for one proportion, or z-test for country-
level analysis) was used. For country-level analysis, the statistical power for
each country was computed using G*Power 3.1 program [20]. When the
analysis involved countries being grouped together, weighted averages
were used for the sex ratio at birth as follows:
Xn
i¼ 1
ðno: of patients  sex ratio at birth in country#iÞ=
Xn
i¼ 1
no: of patients in country#i
Further analyses were performed to test for differences between males
and females in respect to the following variables: (1) age at time of
diagnosis, (2) proportion of familial retinoblastoma, (3) proportion of
bilateral disease, and (4) proportion of cases with advanced disease at time
of diagnosis (≥cT3). Student’s t test was used to test for differences
between means of two groups in case of continuous dependent variables,
and F-test for differences between the groups’ variances. Welch’s
correction was used when differences between variances were found to
be significant. X2 test of independence was used to test for associations
between two categorical variables. P values and confidence intervals (CI)
were corrected for multiple comparisons using the Benjamini–Hochberg
procedure. Summary statistics are presented as mean and 95% CI.
RESULTS
The study sample consists of 4351 patients with retinoblastoma
diagnosed during a single year, of whom 2375 were males and
1976 females, corresponding to an overall sex ratio of 1.20 [95% CI
1.13–1.28]. Over a quarter of the participating countries (44,
28.8%) were lower-middle income, and 42 (27.5%) were in Asia.
Nearly one half of the patients, 1940 (44.6%), came from lower-
middle income countries, and more than one half, 2276 (52.3%)
were from Asia (Table 1). The mean age at time of diagnosis was
27.0 months [95% CI 26.3–27.6], and 3968 (91.2%) patients were
less than 5 years of age. A family history of retinoblastoma was
reported in 199 (4.7%) of 4215 patients for which these data were
available. Bilateral retinoblastoma at time of diagnosis was found
in 1341 (30.8%) of 4351 patients and advanced retinoblastoma
(cT3 or cT4) in 2566 (62.4%) of 4114 patients (Table 2).
Sex ratio differences: national income level and continent
level analysis
Table 1 shows the sex ratio and the corresponding weighted sex
birth ratio for the entire sample and stratified by economic grouping
and continent. The calculated population-weighted global sex ratio
at birth was 1.07, significantly lower than the overall sex ratio in the
present study, 1.20 (95% CI 1.13–1.28, p < 0.001, χ2 test). Significant
differences between the population-weighted sex ratio at birth and
the ratio among patients with retinoblastoma were found in lower-
middle income countries (1.07 vs. 1.22 [95% CI 1.10–1.35],
respectively; corrected p= 0.019, χ2 test) and in Asia (1.06 vs. 1.28
[95% CI 1.15–1.44], respectively; corrected p < 0.001, χ2 test).
On further subgroup analysis at national income and continent
level, no significant differences in the sex ratio were found by age
at retinoblastoma diagnosis, proportion with familial retinoblas-
toma, proportion with bilateral, and proportion with advanced
disease (≥cT3) at time of diagnosis (Table 2).















Total 153 (100) 4351 (100) 2375 (54.6) 1976 (45.4) 1.20 (1.13–1.28) 1.07 <0.001
Economic grouping
Low 28 (18.3) 533 (12.3) 284 (53.3) 249 (46.7) 1.14 (0.94–1.39) 1.04 0.29
Lower-middle 44 (28.8) 1940 (44.6) 1067 (55.0) 873 (45.0) 1.22 (1.10–1.35) 1.07 0.019
Upper-middle 37 (24.2) 1212 (27.9) 654 (54.0) 558 (46.0) 1.17 (1.03–1.33) 1.09 0.22
High 44 (28.8) 666 (15.3) 370 (55.6) 296 (44.4) 1.25 (1.05–1.49) 1.05 0.06
Continent
Africa 43 (28.1) 1024 (23.5) 544 (53.1) 480 (46.9) 1.13 (0.96–1.34) 1.05 0.23
Asia 42 (27.5) 2276 (52.3) 1279 (56.2) 997 (43.8) 1.28 (1.15–1.44) 1.06 <0.001
Europe 40 (26.1) 522 (12.0) 282 (54.0) 240 (46.0) 1.18 (0.93–1.49) 1.09 0.43
LAC 23 (15.0) 312 (7.2) 148 (47.4) 164 (52.6) 0.90 (0.67–1.22) 1.04 0.23
North America 2 (0.7) 200 (4.6) 115 (57.5) 85 (42.5) 1.35 (0.93–2.01) 1.05 0.09
Oceania 3 (2.0) 17 (0.4) 7 (41.2) 10 (58.8) 0.70 (0.13–1.43) 1.06 0.40
CI Confidence interval, LAC Latin America and the Caribbean.















Table 2. Sex differences stratified by age at diagnosis of retinoblastoma and by familial, bilateral, and advanced retinoblastoma; analysis of 4351
patients at national income and continent level.
Males Females p value
National income level
Age at diagnosis of retinoblastoma, months mean (95% CI) Mean (95% CI) Mean (95% CI)
Low: 35.0 (32.5–37.4) 33.7 (31.4–36.2) 32.3 (29.6–35.2) 0.78
Lower-middle: 28.8 (27.8–29.8) 29.0 (27.7–30.2) 28.7 (27.2–30.3) 0.62
Upper-middle: 25.1 (23.7–26.5) 24.6 (22.8–26.6) 25.7 (23.8–27.8) 0.21
High: 20.1 (18.4–21.8) 20.9 (18.5–23.6) 19.2 (17.0–21.4) 0.84
Family history of retinoblastoma n (% within the national income) % (95% CI) % (95% CI)
Low: 15 (3.1) 2.7 (0.7–7.3) 3.5 (0.9–8.8) 0.82
Lower-middle: 75 (4.0) 3.8 (2.3–5.9) 4.2 (2.5–6.7) 0.69
Upper-middle: 54 (4.5) 5.1 (2.9–8.2) 3.8 (1.8–6.9) 0.34
High: 55 (8.4) 8.5 (4.8–13.6) 8.2 (4.2–14.1) >0.99
Bilateral disease n (% within the national income)
Low: 125 (23.5) 21.1 (14.5–29.1) 26.1 (18.4–35.1) 0.21
Lower-middle: 615 (31.7) 33.0 (28.8–37.4) 30.1 (25.6–34.9) 0.19
Upper-middle: 365 (30.1) 31.2 (26.0–36.8) 28.9 (23.4–34.8) 0.41
High: 236 (35.4) 34.1 (27.0–41.7) 37.2 (29.0–45.8) 0.45
Advanced retinoblastomaa n (% within the national income)
Low: 424 (86.4) 83.2 (75.4–89.4) 90.0 (82.8–94.9) 0.13
Lower-middle: 1372 (73.3) 75.0 (70.8–78.8) 71.1 (66.2–75.6) 0.07
Upper-middle: 544 (49.7) 49.9 (43.8–56.0) 49.6 (42.9–56.3) 0.97
High: 226 (34.4) 32.4 (25.4–40.0) 37.0 (28.8–45.8) 0.25
Continent level
Age at diagnosis of retinoblastoma, months mean (95% CI) Mean (95% CI) Mean (95% CI)
Africa: 30.8 (29.6–32.1) 31.4 (29.7–33.4) 30.2 (28.2–32.2) 0.81
Asia: 27.1 (26.2–28.0) 26.8 (25.5–28.0) 27.6 (26.2–29.1) 0.18
Europe: 22.0 (19.6–24.4) 23.8 (20.4–27.8) 19.9 (17.6–22.4) 0.96
LAC: 25.5 (23.1–27.8) 26.8 (23.4–30.1) 24.3 (21.3–27.5) 0.85
North America: 20.1 (16.4–23.8) 18.1 (14.1–23.9) 22.9 (17.7–28.8) 0.10
Oceania: 31.1 (22.0–40.2) 26.1 (15.8–37.2) 34.6 (22.4–47.3) 0.19
Family history of retinoblastoma n (% within the national income) % (95% CI) % (95% CI)
Africa: 26 (2.8) 2.7 (1.0–5.7) 2.9 (1.0–6.3) 0.97
Asia: 94 (4.2) 4.5 (2.9–6.6) 3.9 (2.2–6.0) 0.44
Europe: 43 (8.3) 6.8 (3.0–12.7) 10.2 (5.1–17.6) 0.23
LAC: 15 (4.8) 6.1 (1.7–14.6) 3.7 (6.9–10.6) 0.46
North America: 21 (10.6) 10.5 (3.7–22.1) 10.6 (3.0–24.5) >0.99
Oceania: 0 (0.0) 0.0 (0.0–62.5) 0.0 (0.0–49.7) >0.99
Bilateral disease n (% within the national income)
Africa: 273 (26.7) 23.9 (18.5–29.9) 29.8 (23.6–36.6) 0.24
Asia: 733 (32.2) 33.6 (29.6–37.8) 30.4 (26.0–35.0) 0.11
Europe: 162 (31.0) 32.3 (24.0–41.4) 29.6 (21.0–39.3) 0.57
LAC: 91 (29.2) 31.8 (20.7–44.5) 26.8 (17.0–38.6) 0.41
North America: 79 (39.5) 35.7 (22.6–50.4) 44.7 (28.5–61.8) 0.25
Oceania: 3 (17.6) 42.9 (3.2–92.3) 0.0 (0.0–49.7) 0.10
Advanced Retinoblastomaa n (% within the national income)
Africa: 796 (82.7) 82.1 (76.4–87.0) 83.4 (77.4–88.4) 0.65
Asia: 1282 (60.7) 62.3 (57.9–66.6) 58.7 (53.6–63.7) 0.10
Europe: 197 (38.4) 36.9 (28.2–46.2) 40.2 (30.5–50.4) 0.51
LAC: 212 (67.9) 65.5 (52.7–77.0) 70.1 (58.2–80.4) 0.46
North America: 70 (35.2) 34.8 (21.9–49.5) 35.7 (20.7–53.0) >0.99
Oceania: 9 (52.9) 28.6 (0.7–85.5) 70.0 (20.6–97.8) 0.23
CI Confidence interval, LAC Latin America and the Caribbean.
acT3 or cT4 of the cTNMH classification.
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Sex ratio differences: country-level analysis
Table 3 shows the sex ratio in each participating country and Fig. 1
the sex ratio at birth in each country. Of the 153 countries, a sex
ratio of >1 was found in 85 (55.5%) and a ratio of <1 in 45 (29.4%)
countries, and it equaled 1 in 23 (15.0%) countries.
Figure 2a shows the sex ratio in countries with over 150 patients
as compared to the ratio at birth in these countries. A significant
difference was found only in India (n= 558; sex ratio 1.52 [95% CI
1.24–1.89] vs. 1.11 at birth; corrected p= 0.008, z-test). We did not
find a sex difference in any of the following in India: age at
diagnosis (p= 0.24, t test), proportion of familial retinoblastoma
(p= 0.52, χ2 test), proportion of bilateral disease (p= 0.10, χ2 test),
and proportion of advanced disease (>cT3) at time of diagnosis
(p= 0.81, χ2 test).
Table 3. Sex ratio in 4351 patients from 153 countries diagnosed with Retinoblastoma in 2017: country-level analysis.
Continent Country: Male/Female (ratio)
Africa Algeria: 10/3 (3.33), Angola: 9/8 (1.13), Bénin: 2/0, Botswana: 0/3, Burkina Faso: 14/15 (0.93), Burundi: 9/17 (0.53), Cameroon: 14/20
(0.70), Central African Republic: 2/2 (1.00), Chad: 3/1 (3.00), Cote d’ivoire: 19/13 (1.46), Democratic Republic of Congo: 17/22 (0.77),
Egypt: 75/54 (1.39), Ethiopia: 37/23 (1.61), Gabon: 1/0, Gambia: 1/1 (1.00), Ghana: 19/17 (1.12), Guinea: 1/0, Guinea-Bissau: 1/0,
Kenya: 1/1 (1.00), Liberia: 0/1, Libya: 5/6 (0.83), Madagascar: 4/6 (0.67), Malawi: 10/15 (0.67), Mali: 19/8 (2.38), Mauritania: 4/2 (2.00),
Morocco: 14/15 (0.93), Mozambique: 7/7 (1.00), Niger: 8/8 (1.00), Nigeria: 63/67 (0.94), Republic of the Congo: (1/0), Rwanda: 8/6
(1.33), Sénégal: 12/15 (0.80), Sierra Leone: 0/1, Somalia: 1/0, South Africa: 36/23 (1.57), South Sudan: 3/2 (1.50), Sudan: 5/8 (0.63),
Tanzania: 33/25 (1.32), Togo: 3/2 (1.50), Tunisia: 6/5 (1.20), Uganda: 43/41 (1.05), Zambia: 11/7 (1.57), Zimbabwe: 12/9 (1.33)
Asia Afghanistan: 14/13 (1.08), Azerbaijan: 4/1 (4.00), Bangladesh: 92/69 (1.33), Bhutan: 1/0, Cambodia: 9/13 (0.69), China: 243/216 (1.13),
China, Hong Kong SAR: 3/0, India: 337/221 (1.52), Indonesia: 84/75 (1.12), Iran: 50/25 (2.00), Iraq: 29/35 (0.83), Israel: 6/4 (1.50),
Japan: 18/12 (1.50), Jordan: 8/9 (0.89), Kazakhstan: 19/11 (1.73), Kuwait: 1/1 (1.00), Kyrgyzstan: 6/3 (2.00), Laos: 0/2, Lebanon: 5/2
(2.50), Malaysia: 12/9 (1.33), Mongolia: 1/2 (0.50), Myanmar: 25/21 (1.19), Nepal: 15/7 (2.14), Oman: 1/0, Pakistan: 99/85 (1.16),
Philippines: 19/8 (2.38), Republic of Korea: 9/13 (0.69), Saudi Arabia: 4/1 (4.00), Singapore: 2/2 (1.00), Sri Lanka: 10/8 (1.25), State of
Palestine: 3/3 (1.00), Syria: 3/6 (0.50), Taiwan: 6/7 (0.86), Tajikistan: 1/0, Thailand: 24/16 (1.50), Timor-Leste: 1/0, Turkey: 28/26 (1.08),
Turkmenistan: 1/1 (1.00), United Arab Emirates: 1/0, Uzbekistan: 16/8 (2.00), Vietnam: 61/47 (1.30), Yemen: 8/15 (0.53)
Europe Albania: 2/2 (1.00), Andorra: 0/1, Armenia: 2/1 (2.00), Austria: 5/4 (1.25), Belarus: 3/3 (1.00), Belgium: 2/4 (0.50), Bosnia and
Herzegovina: 1/2 (0.50), Bulgaria: 6/5 (1.20), Croatia: 1/0, Czech Republic: 5/3 (1.67), Denmark: 5/5 (1.00), Estonia: 1/0, Finland: 4/3
(1.33), France: 28.21 (1.33), Georgia: 0/2, Germany: 37/28 (1.32), Greece: 4/0, Hungary: 2/3 (0.67), Ireland: 1/1 (1.00), Italy: 17/14
(1.21), Kosovo: 1/1 (1.00), Latvia: 0/1, Lithuania: 2/0, Macedonia: 1/0, Malta: 0/1, Moldova: 0/3, Netherlands: 8/8 (1.00), Norway: 7/2
(3.50), Poland: 20/8 (2.50), Portugal: 4/1 (4.00), Romania: 5/3 (1.67), Russia: 48/36 (1.33), Serbia: 4/5 (0.80), Slovakia: 1/1 (1.00),
Slovenia: 1/0, Spain: 7/16 (0.44), Sweden: 3/4 (0.75), Switzerland, 2/5 (0.40), United Kingdom: 26/25 (1.04), Ukraine: 16/18 (0.89)
LAC Antigua and Barbuda: 1/0, Argentina: 12/15 (0.80), Bolivia: 2/3 (0.67), Brazil: 29/26 (1.12), Chile: 3/2 (1.5), Colombia: 2/2 (1.00), Costa
Rica: 3/5 (0.60), Cuba: 3/4 (0.75), Dominican Republic: 0/1, Ecuador: 1/1 (1.00), El Salvador: 4/2 (2.00), Guatemala: 13/24 (0.54), Haiti:
4/2 (2.00), Honduras: 0/4, Jamaica: 1/2 (0.50), Mexico: 14/18 (0.78), Nicaragua: 3/2 (1.50), Panama: 1/1 (1.00), Paraguay: 5/5 (1.00),
Peru: 37/37 (1.00), Puerto Rico: 1/0, Uruguay: 1/0, Venezuela: 8/8 (1.00)
North America Canada: 16/8 (2.00), United states: 99/77 (1.29)
Oceania Australia: 4/8 (0.50), New Zealand: 2/2 (1.00), Papua New Guinea: 1/0
LAC Latin America and the Caribbean.
Fig. 1 Sex ratio at birth (M:F) in 153 participating countries. Retrieved from the World Population Prospects.
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The sex ratios in Bangladesh (n= 161), China (n= 459), Indonesia
(n= 159), Pakistan (n= 184), and the United States (n= 176) were
1.33, 1.13, 1.12, 1.16, and 1.29, respectively. Statistical power, given
α= 0.05, was ≤0.29 for all these comparisons that did not show a
difference from the corresponding sex ratio at birth in each country
(p ≥ 0.15, z-test).
Sex ratio differences: sensitivity analysis
On sensitivity analysis, when excluding data from India (Fig. 2b), a
significant difference in the observed sex ratio as compared to the
corresponding population-weighted ratio at birth remained for
the remaining cohort (χ2= 6.925, corrected p= 0.025) and for Asia
as a continent (χ2= 5.084, corrected p= 0.036).
When analysing lower-middle income countries after excluding
India, no significant differences were found (χ2= 0.972, p= 0.32)
and, similarly, none were found when analysing the remaining
cohort with Asia excluded (χ2= 2.205, p= 0.14).
DISCUSSION
Analysis of the entire sample suggests that the null hypothesis of
no sex ratio difference between patients with retinoblastoma
diagnosed in 2017 and the population at risk should be discarded
and that an alternative hypothesis of a male preponderance
corresponding to a sex ratio of 1.20 should be favored. Subgroup
analysis, corrected for multiple comparisons, suggests that the
observed difference in the sex ratio mainly derives from Asia and,
especially, from India, both of which were responsible for a large
part of the sample (over 1/8 of the patients were from India and
over 1/2 from Asia). In the remaining regions, a significant
difference was not observed, suggesting either that the null
hypothesis is true or that, at least for some countries, the sample
size was insufficient to detect a true difference as significant.
One possible explanation for the observed difference in the sex
ratio between Asia and the other continents could be gender-
based discrimination. Gender differences in health and mortality
in India and other South Asian countries have been reported [21–
23]. The “Million Death Study” documented substantial differences
between sexes in India [24]. According to this report, girls aged 5
years or less had significantly higher mortality rates from
infectious causes than boys. In another report, female mortality
in the age group under 5 years exceeded male mortality by 25% in
nearly all states of India (corresponding to about 74,000 excess
deaths in girls) [25]. It has been stated that inequities in access to
care were a more plausible explanation than biological factors for
the recorded differences between sexes in these studies.
Gender-based discrimination by means of neglect of girls in
preventive and curative healthcare has also been reported in Nepal
[26], Bangladesh [27, 28], Pakistan [29], and China [30]. In our study,
we did not observe significant differences in sex ratio in these
countries, although the relatively small samples in each of them
may have precluded identification of such a difference.
A systematic review of gender inequalities in access to surgery for
bilateral cataract among children in low-income countries found
that girls had significantly lower access in some regions than boys,
especially in the Asia region [31]. In retinoblastoma, which is a fatal
cancer if not treated, but curable if diagnosed and treated early,
gender-based discrimination has been reported only anecdotally; a
retrospective analysis of 602 patients with retinoblastoma who
presented to a center in northern India from 2000 to 2014 reported
a sex ratio of 1.56 [32]. The authors concluded that “a male
preponderance in childhood cancers in Indian studies is typical and
often attributed to a bias for preferential care of male children in the
society”. Interestingly, in their study the authors also found that
treatment noncompliance was more common for females than
males (64% vs. 36%; p= 0.02), supporting the same conclusion. In a
study investigating the clinical presentation and outcome of 600
children diagnosed with retinoblastoma in New Delhi in north India
from 2009 to 2013, the sex ratio was 1.58 [33]. The authors
suggested that the excess of male patients was due to gender-
based referral bias. It should be noted, however, that a sex ratio of
1.5 or more (before correcting for sex ratio at birth) has not been
reported in all large-cohort studies on retinoblastoma in India.
Moreover, a study on presentation and outcome of 1,457 patients
diagnosed with retinoblastoma in Hyderabad in south India from
2000 to 2015 reported a sex ratio of 1.26 [34]. It has been suggested
that differences between districts and regions in India may have a
role in this context [24].
Given our findings and the previous literature on gender-based
discrimination, our conclusion is that the observed sex ratio in the
present study is not biological but gender-related, due to
environmental and societal factors (i.e., social, political and/or
cultural) [35].
Fig. 2 Sex ratio in the sample and sex ration at birth. a Sex ratio in
countries with samples of over 150 patients and corresponding sex
ratio at birth. Black dot—sex ratio in each country, bars—95%
confidence interval of the sex ratio, and red dot—sex ratio at birth.
Significant differences were found only in India (corrected p=
0.008). b Sex ratio on whole sample analysis, lower-middle income
countries and Asia, with data from India excluded, and correspond-
ing sex ratio at birth. Black dot—sex ratio in each region/continent,
bars—95% confidence interval of the sex ratio, and red dot—sex
ratio at birth. On two-sided proportions test, differences were found
to be significant only on whole sample analysis (p= 0.025) and
analysis of Asian countries (corrected p= 0.036).
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In our study, girls and boys presented at the same age and
were diagnosed with the same disease stage, including in Asia
and India. These findings support the hypothesis that there is no
biological, sex-related difference in retinoblastoma. With respect
to gender-based discrimination, a possible explanation for our
findings is that once parents/guardians noticed an ocular
abnormality, the main decision was whether or not to access
services, with no delay in accessing services by parents who
decided to do so. These, however, are only assumptions that
necessitate further investigation.
This study has several limitations. We did not take into account
sex differences in infant deaths. However, even in regions with a
relatively high infant mortality rate (e.g., about 8% of all live births
in south Asia) [36], the impact on our analysis would be small. If
anything, assuming that retinoblastoma affects males and females
equally, and because globally more boys die than girls [19], it is
likely that our findings are an underestimation of the real
difference in sex ratio. Another limitation is the study period of
1 year, which yielded just under 4,500 patients. As evidenced in
the post-hoc statistical power calculation, the sample size was
insufficient when broken down to country level. That said, this
study, to the best of our knowledge, is the largest study of
retinoblastoma in terms of sample size, and the most geographi-
cally comprehensive.
In summary, we aimed to investigate whether there are sex
ratio differences in retinoblastoma in a large global sample and
found no consistent support for this assumption, data which are
useful for epidemiologists, geneticists and other medical practi-
tioners in the field. However, we found suggestive evidence that
gender discrimination in favor of boys may exist for patients with
retinoblastoma in certain Asian countries, particularly in India.
These findings, which add to existing literature on gender-based
discrimination in child health in parts of South Asia, can be
used by researchers and policy makers to address gender-based
inequities.
SUMMARY
What was known before
● It is not clear whether there are sex differences in
retinoblastoma, the most common intraocular malignancy of
childhood.
● The literature on retinoblastoma disease consists mainly of
small, single-centre case series.
● In the vast majority of studies, the question of sex ratio
associated with retinoblastoma was not addressed, and in
most, the retinoblastoma sex ratio was not compared to the
sex ratio at birth.
● In the few studies in which retinoblastoma sex ratio was
investigated, results were mixed, showing male, female or no
sex predilection at all.
What this study adds
● This study reports the largest sample of retinoblastoma
patients to date, including over half of the estimated annual
global incidence of cases. It therefore allows for the first time
to answer the sex question.
● Findings of the present analysis suggest that there is no sex
predilection associated with retinoblastoma.
● However, they suggest that differences do exist in specific
countries, mainly in in Asia, India in specific, and are probably
related to gender discrimination in this region.
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